Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBX-102-02
- Development stage
- Unknown
- Lead developer
- EnteroBiotix
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EBX-102-02 is a next-generation, full-spectrum microbiome therapeutic developed by EnteroBiotix for the treatment of diseases linked to gut microbiome dysbiosis, including irritable bowel syndrome (IBS) and liver cirrhosis. It is formulated as an orally administered capsule containing highly diverse microbial ecosystems and key functional groups designed to restore and fortify the intestinal microbiota. The mechanism of action involves modulating the gut microbiome composition, leading to improved gastrointestinal symptoms such as stool consistency, bowel movement frequency, and abdominal pain in IBS patients. Clinical studies have shown that EBX-102-02 induces a significant shift in patients' intestinal microbiota toward a healthier profile similar to that of the product itself. The drug has demonstrated favorable safety and tolerability profiles in Phase 2a trials for IBS with constipation (IBS-C), with plans for further development in both IBS subtypes and liver-related indications[1][3][4][6].
- Other names
- EBX-102-02 single doseEBX102-02 single doseEBX 102-02 single dose
Beyond the preview
Go deeper on EBX-102-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBX-102-02.